![Frederick Jones](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Dr. Frederick Jones, MD MBA, is President & Chief Executive Officer at Anchor Therapeutics, Inc.
Dr. Jones was previously employed as Vice President-Business Development by BioRexis Pharmaceutical Corp., a Faculty Member by University of Pennsylvania, a Principal by Global Business Group Pty Ltd., and a Principal by Wyeth Corp.
He received his undergraduate degree from the University of Pennsylvania, an MBA from the University of Pennsylvania, and a doctorate degree from the University of Pennsylvania.
Former positions of Frederick Jones
Companies | Position | End |
---|---|---|
BioRexis Pharmaceutical Corp.
![]() BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | Corporate Officer/Principal | 01/01/2007 |
University of Pennsylvania | Corporate Officer/Principal | - |
Global Business Group Pty Ltd.
![]() Global Business Group Pty Ltd. Internet Software/ServicesTechnology Services Part of Dolphin Entertainment, Inc., Global Business Group Pty Ltd. engages in the business of selling consumer goods online and through published catalogs. The company is based in Bundall, Australia. Global Business Group was acquired by Maximum Awards, Inc. on June 01, 2004 for $0.0 million. | Corporate Officer/Principal | - |
Wyeth Corp.
![]() Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Corporate Officer/Principal | - |
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Chief Executive Officer | - |
Training of Frederick Jones
University of Pennsylvania | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Anchor Therapeutics, Inc.
![]() Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
BioRexis Pharmaceutical Corp.
![]() BioRexis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology BioRexis Pharmaceutical Corp. provides novel protein and peptide drugs with pharmacology and trans-bodies to replace conventional monoclonal antibodies. The company was founded by Christopher P. Prior, Andrew Turner and David R. King in 2002 and is headquartered in Rosemont, PA. | Health Technology |
Wyeth Corp.
![]() Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Global Business Group Pty Ltd.
![]() Global Business Group Pty Ltd. Internet Software/ServicesTechnology Services Part of Dolphin Entertainment, Inc., Global Business Group Pty Ltd. engages in the business of selling consumer goods online and through published catalogs. The company is based in Bundall, Australia. Global Business Group was acquired by Maximum Awards, Inc. on June 01, 2004 for $0.0 million. | Technology Services |
- Stock Market
- Insiders
- Frederick Jones